ALMS ALUMIS INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1847367 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-72.6%
TTM EPS YoY-64.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-6,116.7%
Net margin-5,844.5%
FCF margin-4,433.3%
EBITDA margin-6,069.2%
Returns
ROE-110.9%
ROA-86.6%
ROIC (approx.)-109.3%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets22.6%
Debt / equity0.00x
Current ratio5.57x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.76x
Accruals ratio-21.1%
Payout ratio—
Capex / revenue11.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|---|
| Income statement | |||
| Revenue | $24.05M | — | — |
| R&D expense | $386.00M | $265.55M | $137.68M |
| SG&A expense | $91.86M | $35.20M | $20.50M |
| Operating income | -$453.80M | -$300.75M | -$158.17M |
| Pretax income | -$251.89M | -$294.23M | — |
| Income tax | -$8.56M | $0 | $0 |
| Net income | -$243.32M | -$294.23M | -$154.99M |
| EBITDA | -$450.31M | -$297.60M | -$156.89M |
| EPS (basic) | -2.86 | -10.38 | -72.08 |
| EPS (diluted) | -2.86 | -10.38 | -72.08 |
| Weighted avg. shares (diluted) | 85.03M | 28.34M | 2.15M |
| Balance sheet | |||
| Cash & equivalents | $89.67M | $170.63M | $47.13M |
| Short-term investments | $218.83M | $118.74M | $2.96M |
| Current assets | $318.23M | $306.19M | $53.36M |
| PP&E, net | $18.19M | $20.97M | $22.44M |
| Total assets | $411.94M | $340.99M | $89.61M |
| Current liabilities | $73.32M | $50.91M | $20.87M |
| Total liabilities | $110.64M | $80.89M | $53.50M |
| Shareholders' equity | $301.30M | $260.10M | -$339.26M |
| Cash flow statement | |||
| Operating cash flow | -$369.52M | -$255.08M | -$129.97M |
| Capital expenditure | $653,000 | $1.73M | $4.50M |
| Free cash flow | -$370.18M | -$256.81M | -$134.47M |
| Investing cash flow | $287.88M | -$113.79M | $60.47M |
| Financing cash flow | $2.07M | $492.37M | $89.68M |
| Depreciation & amortization | $3.50M | $3.15M | $1.28M |
| Stock-based compensation | $43.52M | $19.46M | $8.62M |
| Share buybacks | $17,000 | $6,000 | $64,000 |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.